



TO THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: HARRIS et al.

Serial No. 10/560,290

Filed: December 12, 2005

For: PIPERIDINE DERIVATIVES AS MELANOCORTIN-4
RECEPTOR AGONISTS

Art Unit: --

Examiner: --

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Buerbel Brown Date 2/27/06

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- the attached information is filed within three months of the filing date of the captioned case.
- the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,

Barbel R. Brown

By: BAERBEL R. BROWN

Attorney _____ For Applicant(s)

Reg. No. 47,449

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-0672

Date: February 27, 2006

Substitute for form 1449A/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE		Application Number	10/560,290
STATEMENT BY APPLICANT		Filing Date	December 12, 2005
<i>(use as many sheets as necessary)</i>		First Named Inventor	H. Sings et al.
		Group Art Unit	--
		Examiner Name	--
TRADEMARKS sheet	1	of	Attorney Docket Number

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Signature _____ **Date Considered** _____

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer-generated form "IDS Form" (IDS Folder), Merck & Co., Inc. -7/12/2005

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				COMPLETE IF KNOWN	
Sheet	2	of	3	Application Number	10/560,290
				Filing Date	December 12, 2005
				First Named Inventor	H. Sings et al.
				Group Art Unit	--
				Examiner Name	--
				Attorney Docket Number	21278P

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	AA	Kopelman, Nature, Vol. 404 (2000), pp. 635-643, "Obesity as a medical problem"
	AB	Huszar et al., Cell, Vol. 88 (1997), pp. 131-141, "Targeted disruption of the melanocortin-4 receptor results in obesity in mice"
	AC	Kask et al., Biochem. & Biophys. Res. Comm., Vol. 245 (1998), pp. 90-93, "Selected antagonist for the melanocortin 4 receptor (HSO014) increases food intake in free-feeding rats"
	AD	Chen et al., Cell, Vol. 91 (1997), pp. 789-798, "Exocrine gland dysfunction in MC5-R-deficient mice ..."
	AE	Giraudo et al., Brain Res., Vol. 809 (1998), pp. 302-306, "Feeding effects of hypothalamic injection of melanocortin 4 receptor ligands"
	AF	Hill et al. Science, Vol. 280 (1998), pp. 1371-1374, "Environmental contributions to the obesity epidemic"
	AG	Corcos et al., Society for Neuroscience Abstracts, Vol. 23 (1997), Abstract No. 267.9, p. 673, "HP 228 is a potent agonist of melanocortin receptor 4, and significantly attenuates obesity and diabetes in Zucker fatty rats"
	AH	Peptides: Frontiers of Peptide Science, Proceedings of the 15th American Peptide Symposium, June 14-19, 1997, Nashville, TN
	AI	Wessels et al., J. of Urology, Vol. 160 (1998), pp. 389-393, "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction ..."
	AJ	Dorr et al., Life Sciences, Vol. 58, No. 20 (1996), pp. 1777-1784, "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study"
	AK	Wessells et al., Urology, Vol. 56 (2000), pp. 641-646, "Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction"
	AL	Graul, Drugs News & Perspectives, Vol. 9 (1996), pp. 572-575, "Latest findings on the diagnosis and treatment of erectile dysfunction"
	AM	Dinsmore et al., Brit. Med. J., Vol. 318 (1999), pp. 387-390, "ABC of sexual health -- erectile dysfunction"
	AN	Gingell et al., Exp. Opin. Ther. Patents, Vol. 9 (1999), pp. 1689-1696, "Emerging pharmacological therapies for erectile dysfunction"
	AO	Yoram et al., Current Opinion in Urology, Vol. 7 (1997), pp. 349-353, "Oral pharmacotherapy in erectile dysfunction"

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE</p> <p>STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				COMPLETE IF KNOWN	
				Application Number	10/560,290
				Filing Date	December 12, 2005
				First Named Inventor	H. Sings et al.
				Group Art Unit	--
				Examiner Name	--
Sheet	3	of	3	Attorney Docket Number	21278P

NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005